Cargando…

Effect of COVID-19 in Pulmonary Hypertension

Detalles Bibliográficos
Autor principal:	Jha, Ajay Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940140/ https://www.ncbi.nlm.nih.gov/pubmed/36252237 http://dx.doi.org/10.1164/rccm.202209-1790LE

Ejemplares similares

Pulmonary Vascular Changes in Acute Respiratory Distress Syndrome due to COVID-19
por: Jha, Ajay Kumar
Publicado: (2021)

Addition of 5% CO(2) to Inspiratory Gas in Preventing Lung Injury Due to Pulmonary Artery Ligation
por: Jha, Ajay Kumar
Publicado: (2021)

Incidence and outcomes of COVID-19 in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Data from the Hellenic pulmOnary hyPertension rEgistry (HOPE)
por: Farmakis, Ioannis T., et al.
Publicado: (2022)

Transpulmonary Bubble Transit in Severe COVID-19: Pulmonary Vasodilatation or Angiogenesis?
por: Chiang, Kate Chander, et al.
Publicado: (2021)

Hypertension and severe COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2023)

Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection
por: Zamanian, Roham T., et al.
Publicado: (2020)

Reduced Rate of Hospital Admissions for heart failure and pulmonary hypertension during Covid-19 infection. Monocentric experience
por: Serra, Walter
Publicado: (2021)

Transvenous Phrenic Nerve Stimulation in Patients Who Are Difficult to Wean
por: Jha, Ajay Kumar
Publicado: (2022)

Continued Vigorous Inspiratory Effort as a Predictor of Noninvasive Ventilation Failure
por: Jha, Ajay Kumar
Publicado: (2020)

Anatomical, physiological and clinical similarities and differences in ARDS physiological subtypes
por: Jha, Ajay Kumar
Publicado: (2021)

Understanding the Pathophysiological and Clinical Changes in Lung Injury Models
por: Jha, Ajay Kumar
Publicado: (2023)

Reply to: Hypertension and severe COVID-19
por: Shibata, Shigeru, et al.
Publicado: (2023)

Cognitive Dysfunction in Patients with Pulmonary Hypertension
por: Yuan, Ping, et al.
Publicado: (2022)

Learning curve and analysis of curative effects after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
por: Hong, Cheng, et al.
Publicado: (2023)

Can Pulmonary Arterial Compliance Be a Prognostic Marker for Pulmonary Hypertension?
por: Wu, Yanjuan, et al.
Publicado: (2023)

Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?
por: Weatherald, Jason, et al.
Publicado: (2021)

COVID-19–associated Pulmonary Aspergillosis
por: van Arkel, Andreas L. E., et al.
Publicado: (2020)

Effect of COVID-19 on maternal and neonatal services
por: Jha, Deepak, et al.
Publicado: (2021)

Pulmonary Hypertension in Glycogen Storage Disease Type II
por: Li, Hui-Ping, et al.
Publicado: (2018)

Pulmonary Hypertension: A Predictor of Lung Cancer Prognosis?
por: Zheng, Zhenzhen, et al.
Publicado: (2021)

Pulmonary edema in COVID-19: Explained by bradykinin?
por: Zwaveling, Suzanne, et al.
Publicado: (2020)

Covid-19 and in situ pulmonary artery thrombosis
por: Mandal, Amit K.J., et al.
Publicado: (2021)

Incidence of pulmonary embolism in patients with COVID-19
por: Rech, Tatiana Helena, et al.
Publicado: (2020)

Surveillance for COVID-19-associated pulmonary aspergillosis
por: Brown, Li-An K, et al.
Publicado: (2020)

Pulmonary Vasculature: A Target for COVID-19
por: Chen, Lingdan, et al.
Publicado: (2021)

A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension
por: Mohamed, Nura A., et al.
Publicado: (2016)

BET Signaling: A Novel Therapeutic Target for Pulmonary Hypertension?
por: Chen, Lingdan, et al.
Publicado: (2020)

Counting the global COVID-19 dead
por: Jha, Prabhat, et al.
Publicado: (2022)

Pulmonary rehabilitation in COVID-19 pneumonia sequelae: so near yet so far
por: Hussain, Aqeel, et al.
Publicado: (2021)

Targeting Pulmonary Hypertension Caused by Pulmonary Fibrosis: A Promising Natural Killer T Cell–based Therapy
por: Wang, Zi-Hao, et al.
Publicado: (2023)

Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension
por: Li, Gang, et al.
Publicado: (2020)

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
por: Fang, Lei, et al.
Publicado: (2020)

Clinical implication of pulmonary artery thrombi in COVID-19
por: Zotzmann, Viviane, et al.
Publicado: (2021)

Pulmonary embolism and COVID-19: A paradigm change()
por: Franco-Moreno, A., et al.
Publicado: (2020)

Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis
por: Jabeen, Kauser, et al.
Publicado: (2021)

Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis
por: Permpalung, Nitipong, et al.
Publicado: (2021)

BET Bromodomain Inhibitors and Pulmonary Arterial Hypertension: Take Care of the Heart
por: Piquereau, Jérôme, et al.
Publicado: (2019)

More Insights into the Association between RVX-208 and Pulmonary Arterial Hypertension
por: Ning, Dong, et al.
Publicado: (2020)

circGSAP: A New Clinical Biomarker for Idiopathic Pulmonary Hypertension?
por: Sun, Xishi, et al.
Publicado: (2021)

Treatment of Pulmonary Hypertension: Is Triple Therapy Necessarily Better than Monotherapy?
por: Sun, Xishi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4bs9q0p9tguia270kfohjmjhjn